Kopran Ltd is launching 12 new brands in the field of asthma, cardiology, gastroenterology and diabetology.

In the anti-asthma market, Kopran has a large range of products including oral tablets and liquids, metered dose inhalers and dry powder inhalers under the umbrella brand Vent which has a sales of Rs15 crores during previous year and are estimated to jump to Rs 25 crores with the launch of the new anti-asthma products.

Kopran is now launching Ventair (Montelukast), a new drug for asthma, bridging the gap in the present asthma treatment for both children and adults. Ventair will be marketed in 3 doses i.e., 10mg. coated tablets and 4mg, and 5mg, moth soluble tablets incorporating Kopran's Orasolve Technology. Kopran is the fourth company to launch Montelukast.

Kopran is also synthesizing the bulk drug. It also plans to co-market this product with other companies.

Simultaneously, Kopran is launching a new dry powder inhaler and metered dose inhaler - Ventipra - a combination of Salbutamol and Ipratropium bromide.

The anti-asthma products are marketed by Kopran in the KResp Division - a division dedicated to asthma care. At present, only three companies in India, viz Glaxo, Cipla and Kopran, market dry powder inhalation systems.

In cardiology, Kopran is launching Carvedilol, one of the new beta-blockers under the name Caditone. Carvedilol is a newer anti-hypertensive growing at the annual rate of 41 per cent.

Kopran has reformulated its brand of Amlodipine -Klodip - introducing virtually impurity free Amlodipine tablets in a new patient friendly pack.

The Amlodipine market Rs. 116 crores strong, and growing at 15 per cent per annum. Klodip would give a boost to Kopran's presence in the Cardiology segment. The virtually impurity free Amlodipine bulk is being made by Kopran in its Mahad Plant and they expect to file their own process patent for the same.

Other products to be launched include Clopidogrel and Candesartan in cardiology, Rabeprazole and Mosapride in gastro-enterology and Pioglitazone in anti-diabetic segment.

With such a large basket of new products, Kopran intends to grow its formulation sales to Rs. 100 crores in the next two years.